Skip to main content
Erschienen in: Breast Cancer Research and Treatment 2/2008

01.07.2008 | Preclinical Study

Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants

verfasst von: Christopher A. Pettigrew, Nicola Wayte, Ania Wronski, Paul K. Lovelock, Amanda B. Spurdle, Melissa A. Brown

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 2/2008

Einloggen, um Zugang zu erhalten

Abstract

Disruption of the breast cancer susceptibility gene BRCA2 is associated with increased risk of developing breast and ovarian cancer. Over 1800 sequence changes in BRCA2 have been reported, although for many the pathogenicity is unclear. Classifying these changes remains a challenge, as they may disrupt regulatory sequences as well as the primary protein coding sequence. Sequence changes located in the splice site consensus sequences often disrupt splicing, however sequence changes located within exons are also able to alter splicing patterns. Unfortunately, the presence of these exonic splicing enhancers (ESEs) and the functional effect of variants within ESEs it is currently difficult to predict. We have previously developed a method of predicting which sequence changes within exons are likely to affect splicing, using BRCA1 as an example. In this paper, we have predicted ESEs in BRCA2 using the web-based tool ESEfinder and incorporated the same series of filters (increased threshold, 125 nt limit and evolutionary conservation of the motif) in order to identify predicted ESEs that are more likely to be functional. Initially 1114 ESEs were predicted for BRCA2, however after all the filters were included, this figure was reduced to 31, 3% of the original number of predicted ESEs. Reported unclassified sequence variants in BRCA2 were found to colocalise to 55% (17/31) of these conserved ESEs, while polymorphisms colocalised to 0 of the conserved ESEs. In summary, we have identified a subset of unclassified sequence variants in BRCA2 that may adversely affect splicing and thereby contribute to BRCA2 disruption.
Literatur
1.
Zurück zum Zitat Wong AK, Pero R, Ormonde PA et al (1997) RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 272(51):31941–31944PubMedCrossRef Wong AK, Pero R, Ormonde PA et al (1997) RAD51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene brca2. J Biol Chem 272(51):31941–31944PubMedCrossRef
2.
Zurück zum Zitat Milner J, Ponder B, Hughes-Davies L et al (1997) Transcriptional activation functions in BRCA2. Nature 386(6627):772–773PubMedCrossRef Milner J, Ponder B, Hughes-Davies L et al (1997) Transcriptional activation functions in BRCA2. Nature 386(6627):772–773PubMedCrossRef
3.
Zurück zum Zitat Fuks F, Milner J, Kouzarides T (1998) BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17(19):2531–2534PubMedCrossRef Fuks F, Milner J, Kouzarides T (1998) BRCA2 associates with acetyltransferase activity when bound to P/CAF. Oncogene 17(19):2531–2534PubMedCrossRef
4.
Zurück zum Zitat Goldgar DE, Easton DF, Deffenbaugh AM et al (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75(4):535–544PubMedCrossRef Goldgar DE, Easton DF, Deffenbaugh AM et al (2004) Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet 75(4):535–544PubMedCrossRef
5.
Zurück zum Zitat Wu K, Hinson SR, Ohashi A et al (2005) Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65(2):417–426PubMedCrossRef Wu K, Hinson SR, Ohashi A et al (2005) Functional evaluation and cancer risk assessment of BRCA2 unclassified variants. Cancer Res 65(2):417–426PubMedCrossRef
6.
Zurück zum Zitat Carvalho MA, Marsillac SM, Karchin R et al (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67(4):1494–1501PubMedCrossRef Carvalho MA, Marsillac SM, Karchin R et al (2007) Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res 67(4):1494–1501PubMedCrossRef
7.
Zurück zum Zitat Chenevix-Trench G, Healey S, Lakhani S et al (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66(4):2019–2027PubMedCrossRef Chenevix-Trench G, Healey S, Lakhani S et al (2006) Genetic and histopathologic evaluation of BRCA1 and BRCA2 DNA sequence variants of unknown clinical significance. Cancer Res 66(4):2019–2027PubMedCrossRef
8.
Zurück zum Zitat Duan J, Wainwright MS, Comeron JM et al (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205–216PubMedCrossRef Duan J, Wainwright MS, Comeron JM et al (2003) Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 12(3):205–216PubMedCrossRef
9.
Zurück zum Zitat Liu HX, Cartegni L, Zhang MQ et al (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27(1):55–58PubMedCrossRef Liu HX, Cartegni L, Zhang MQ et al (2001) A mechanism for exon skipping caused by nonsense or missense mutations in BRCA1 and other genes. Nat Genet 27(1):55–58PubMedCrossRef
10.
Zurück zum Zitat Fackenthal JD, Cartegni L, Krainer AR et al (2002) BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet 71(3):625–631PubMedCrossRef Fackenthal JD, Cartegni L, Krainer AR et al (2002) BRCA2 T2722R is a deleterious allele that causes exon skipping. Am J Hum Genet 71(3):625–631PubMedCrossRef
11.
Zurück zum Zitat Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72:291–336PubMedCrossRef Black DL (2003) Mechanisms of alternative pre-messenger RNA splicing. Annu Rev Biochem 72:291–336PubMedCrossRef
12.
Zurück zum Zitat Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18(4):186–193PubMedCrossRef Caceres JF, Kornblihtt AR (2002) Alternative splicing: multiple control mechanisms and involvement in human disease. Trends Genet 18(4):186–193PubMedCrossRef
13.
Zurück zum Zitat Blencowe BJ (2000) Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 25(3):106–110PubMedCrossRef Blencowe BJ (2000) Exonic splicing enhancers: mechanism of action, diversity and role in human genetic diseases. Trends Biochem Sci 25(3):106–110PubMedCrossRef
14.
Zurück zum Zitat Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3(4):285–298PubMedCrossRef Cartegni L, Chew SL, Krainer AR (2002) Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 3(4):285–298PubMedCrossRef
15.
Zurück zum Zitat Claes K, Poppe B, Machackova E et al (2003) Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer 37(3):314–320PubMedCrossRef Claes K, Poppe B, Machackova E et al (2003) Differentiating pathogenic mutations from polymorphic alterations in the splice sites of BRCA1 and BRCA2. Genes Chromosomes Cancer 37(3):314–320PubMedCrossRef
16.
Zurück zum Zitat Zatkova A, Messiaen L, Vandenbroucke I et al (2004) Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat 24(6):491–501PubMedCrossRef Zatkova A, Messiaen L, Vandenbroucke I et al (2004) Disruption of exonic splicing enhancer elements is the principal cause of exon skipping associated with seven nonsense or missense alleles of NF1. Hum Mutat 24(6):491–501PubMedCrossRef
17.
Zurück zum Zitat Pagenstecher C, Wehner M, Friedl W et al (2006) Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet 119(1–2):9–22PubMedCrossRef Pagenstecher C, Wehner M, Friedl W et al (2006) Aberrant splicing in MLH1 and MSH2 due to exonic and intronic variants. Hum Genet 119(1–2):9–22PubMedCrossRef
18.
Zurück zum Zitat Cartegni L, Wang J, Zhu Z et al (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31(13):3568–3571PubMedCrossRef Cartegni L, Wang J, Zhu Z et al (2003) ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 31(13):3568–3571PubMedCrossRef
19.
Zurück zum Zitat Gorlov IP, Gorlova OY, Frazier ML et al (2004) Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs). Mutat Res 554(1–2):175–183PubMed Gorlov IP, Gorlova OY, Frazier ML et al (2004) Missense mutations in cancer suppressor gene TP53 are colocalized with exonic splicing enhancers (ESEs). Mutat Res 554(1–2):175–183PubMed
20.
Zurück zum Zitat Pettigrew C, Wayte N, Lovelock PK et al (2005) Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms. Breast Cancer Res 7(6):R929–R939PubMedCrossRef Pettigrew C, Wayte N, Lovelock PK et al (2005) Evolutionary conservation analysis increases the colocalization of predicted exonic splicing enhancers in the BRCA1 gene with missense sequence changes and in-frame deletions, but not polymorphisms. Breast Cancer Res 7(6):R929–R939PubMedCrossRef
21.
Zurück zum Zitat Majewski J, Ott J (2002) Distribution and characterization of regulatory elements in the human genome. Genome Res 12(12):1827–1836PubMedCrossRef Majewski J, Ott J (2002) Distribution and characterization of regulatory elements in the human genome. Genome Res 12(12):1827–1836PubMedCrossRef
22.
Zurück zum Zitat Tavtigian SV, Deffenbaugh AM, Yin L et al (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43(4):295–305PubMedCrossRef Tavtigian SV, Deffenbaugh AM, Yin L et al (2006) Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. J Med Genet 43(4):295–305PubMedCrossRef
23.
Zurück zum Zitat Mathe E, Olivier M, Kato S et al (2006) Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34(5):1317–1325PubMedCrossRef Mathe E, Olivier M, Kato S et al (2006) Computational approaches for predicting the biological effect of p53 missense mutations: a comparison of three sequence analysis based methods. Nucleic Acids Res 34(5):1317–1325PubMedCrossRef
24.
Zurück zum Zitat Gorlov IP, Gorlova OY, Frazier ML et al (2003) Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers. Am J Hum Genet 73(5):1157–1161PubMedCrossRef Gorlov IP, Gorlova OY, Frazier ML et al (2003) Missense mutations in hMLH1 and hMSH2 are associated with exonic splicing enhancers. Am J Hum Genet 73(5):1157–1161PubMedCrossRef
25.
Zurück zum Zitat Ghosh A, Stewart D, Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24(18):7987–7997PubMedCrossRef Ghosh A, Stewart D, Matlashewski G (2004) Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 24(18):7987–7997PubMedCrossRef
26.
Zurück zum Zitat Courtois S, Verhaegh G, North S et al (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21(44):6722–6728PubMedCrossRef Courtois S, Verhaegh G, North S et al (2002) DeltaN-p53, a natural isoform of p53 lacking the first transactivation domain, counteracts growth suppression by wild-type p53. Oncogene 21(44):6722–6728PubMedCrossRef
27.
Zurück zum Zitat Orban TI, Olah E (2003) Emerging roles of BRCA1 alternative splicing. Mol Pathol 56(4):191–197PubMedCrossRef Orban TI, Olah E (2003) Emerging roles of BRCA1 alternative splicing. Mol Pathol 56(4):191–197PubMedCrossRef
28.
Zurück zum Zitat Graveley BR, Hertel KJ, Maniatis T (1998) A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers. EMBO J 17(22):6747–6756PubMedCrossRef Graveley BR, Hertel KJ, Maniatis T (1998) A systematic analysis of the factors that determine the strength of pre-mRNA splicing enhancers. EMBO J 17(22):6747–6756PubMedCrossRef
29.
Zurück zum Zitat Wu Y, Zhang Y, Zhang J (2005) Distribution of exonic splicing enhancer elements in human genes. Genomics 86(3):329–336PubMedCrossRef Wu Y, Zhang Y, Zhang J (2005) Distribution of exonic splicing enhancer elements in human genes. Genomics 86(3):329–336PubMedCrossRef
Metadaten
Titel
Colocalisation of predicted exonic splicing enhancers in BRCA2 with reported sequence variants
verfasst von
Christopher A. Pettigrew
Nicola Wayte
Ania Wronski
Paul K. Lovelock
Amanda B. Spurdle
Melissa A. Brown
Publikationsdatum
01.07.2008
Verlag
Springer US
Erschienen in
Breast Cancer Research and Treatment / Ausgabe 2/2008
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9714-5

Weitere Artikel der Ausgabe 2/2008

Breast Cancer Research and Treatment 2/2008 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.